Armis Named ‘Outperformer’ and ‘Leader’ in GigaOm Radar Report for Operational Technology Security for Second Consecutive Year
Armis, the asset intelligence cybersecurity company, today announced that it has been named a Leader and Outperformer in the 2024 GigaOm Radar Report for Operational Technology (OT) Security. This is the second year running is recognized as a Leader in the field of OT Security, cementing its status as a mature platform solution providing proactive end-to-end security for cross-vertical organizations looking for a cohesive approach to OT Security management.
Armis scored multiple 5/5 perfect scores showcasing Armis’ customer-centric vision to deliver OT security built on deep asset context, proactive threat intelligence and total vulnerability management. From cost and ease of use to scalability and flexibility and certification, Armis was recognized for being built for smooth deployment in OT environments.
“The on-going development of the Armis Centrix™ platform has enabled us to offer complete end to end OT security management from complete visibility, vulnerability remediation and management through to advanced AI threat detection,” said Yevgeny Dibrov, CEO and Co-founder of Armis. “I am grateful to GigaOm for recognizing, not just our leadership position, but also awarding us 'Outperformer status', praising the developments we have made this past year.”
The GigaOm Radar is a thoroughly comprehensive technology analysis of OT security solutions on the market today, focusing on the latest innovation and critical capabilities that customers need to protect their entire environment. It also benchmarks current solutions and is able to effectively track how OT/ICS security has evolved in order to stay ahead of modern threat actors and attack vectors.
“Armis has excelled in rapidly advancing its technological offerings and has notably enhanced its threat detection capabilities over the past year, pushing the boundaries of innovation in OT security,” said Chris Ray, Research Analyst at GigaOm. “Armis is positioned as a Platform Play because it offers an extensive and integrated security platform capable of addressing multiple OT security concerns, making it well-suited for organizations seeking comprehensive solutions. It is classified as Innovative due to its aggressive approach in introducing new features and capabilities, which highlights its commitment to staying ahead in technology advancements. Armis has achieved Leader status thanks to its effective market penetration and the robustness of its security solutions.”
Within the GigaOm Radar for OT Security, Armis Centrix™ is recognized for:
- Asset Discovery - Armis' automated asset discovery feature received a 5/5 score for surpassing traditional methods by incorporating passive network discovery, active asset querying techniques, integration-based approaches, and asset profiling. This thorough strategy ensures precise identification of all devices, managed or unmanaged, granting organizations a complete view of their network landscape.
- Dynamic Network Segmentation - Additionally, Armis received a 5/5 score for its dynamic network segmentation, utilizing knowledge of VLANs, subnets, and wireless networks to create device segments as the dynamic attack surface requires, and provide insights into architectural changes for more secure environments.
- Managing Complex, Converged Environments - Armis demonstrated proficiency in managing diverse environments, including the OT, IT, IoT, and medical sectors. Armis Centrix™ showcased strong adherence to industry standards and regulatory requirements, scoring a 5/5 for business certification criterion thus instilling trust and confidence in its customers. Notable certifications include FedRAMP, DoD Impact Level 4, ISO 27001, ISO 28018, and SOC 2 type 2.
- Next-Generation AI Threat Detection - With the addition of actionable threat intelligence capabilities this year Armis displayed huge growth in AI technologies for threat detection. Scoring a 5/5, Armis was applauded for using AI to identify attacks still in the formulation stage as well as pinpointing anomalous behavior, unusual activities, malicious code, and other threats in real time. Armis integrates with SIEM, SOAR, XDR, and ASM solutions, ensuring comprehensive coverage and visibility across the entire attack surface.
- Integration with IT security systems - Ensuring coordinated security efforts across both IT and OT environments. This convergence enhances the overall cybersecurity posture of an organization, addressing complex, multifaceted threats that span the IT-OT divide.
- Providing visualization of OT asset relationships - Offering best-in-class dashboards and Purdue modeling to represent how OT assets connect and interact within an organization's network. This visibility is essential for understanding potential pathways of cyber threats and optimizing security responses.
“Armis offers a comprehensive suite of security features well-suited for SMBs, large enterprises, and public sector organizations,” continued Ray. “Leaders like Armis demonstrate robust platform capabilities with wide-reaching security features, making them stalwarts in the industry.”
The 2024 GigaOm Radar Report is a valuable resource for organizations aiming to enhance their OT security posture. It offers a thorough overview of the OT security market and highlights the leading vendors in the space. To learn more, read the Armis blog highlighting key findings from this year’s report here.
About Armis
Armis, the asset intelligence cybersecurity company, protects the entire attack surface and manages the organization’s cyber risk exposure in real time. In a rapidly evolving, perimeter-less world Armis ensures that organizations continuously see, protect and manage all critical assets – from the ground to the cloud. Armis secures Fortune 100, 200 and 500 companies as well as national governments, state and local entities to help keep critical infrastructure, economies and society stay safe and secure 24/7. Armis is a privately held company headquartered in California.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624790874/en/
Contacts
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 11:53:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom